Preview Part 1 (SNTA, ASTX, NVS, INFI)
Preview Part 2
Preview Part 3 (ARRY, ASTX)
Preview Part 4 (ASTX, ARQL, BPAX)
Preview Part 5 (TKMR, EXEL, PCYC, IMMU, VRTX)
Preview Part 6 (CRIS INFI ISIS CLDX LGND PCYC)
Characterization of effects of M402 on EMT in pancreatic ductal adenocarcinoma (Abstract 302) Momenta Pharma $MNTA
Clusterin downregulation sensitize prostate cancer cells to taxane by modulating mitosis (Abstract 4062) OncoGenex Pharmaceuticals $OGXI and Teva Pharmaceuticals $TEVA
Hsp27 is an essential effector of EGF-induced epithelial to mesenchymal transition in prostate cancer (Abstract 201) Oncogenex Pharmaceuticals $OGXI
Molecular mechanisms of elesclomol cytotoxicity (Abstract 5559) Synta Pharmaceuticals $SNTA
See links for preview parts 1 and 2 above for numerous other abstracts related to SNTA's lead drug ganetespib.
Selectively kill cisplatin resistant lung cancer cells by exploiting ROS and metabolic differences (Abstract 961) Synta Pharmaceuticals $SNTA
Phase I study of histone deacetylase inhibitor belinostat in combination with warfarin in patients with solid tumors or hematological malignancies (Abstract 1172) Spectrum Pharmaceuticals $SPPI with partner TopoTarget
Nanoparticle based combinatorial siRNA therapy against human hepatocellular carcinoma (HCC) (Abstract 5661) Tekmira Pharmaceuticals $TKMR
See part 5 link above for late-breaking TKMR phase 1 clinical trial abstract.